The Centers for Medicare & Medicaid Services (CMS) recently published its Proposed 2026 Physician Fee Schedule Rule (Proposed Rule), with extensive implications for drug pricing, Average Sales Price ...
Drug manufacturers, group purchasing organizations, and other companies in the drug distribution chain will be impacted by the changes to average sales price (ASP) and bona fide service fees (BFSFs) ...
CMS’s 2026 requirement for manufacturers to submit “reasonable assumptions” alongside ASP data formalizes the role of estimation in drug pricing, increasing scrutiny on how ASP is constructed and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results